Can you take Trulicity injections for weight loss?

Ready to take the next step? See if you're eligible for expert-led weight loss support.

Check your eligibility

Trulicity is not an approved treatment for weight loss, but Wegovy and Mounjaro are effective and approved alternatives. Learn more in our guide.



Injectable weight loss medications are getting more popular as a convenient and effective way to lose weight alongside a healthy diet and lifestyle.
The two most commonly prescribed weight loss injections are Wegovy (semaglutide) and Mounjaro (tirzepatide) . These medications are known as 'GLP-1 receptor agonists' – they mimic a natural hormone called 'GLP-1', which is involved in appetite control and blood sugar management.
Trulicity (dulaglutide) is also a GLP-1 receptor agonist. So, it's natural you might wonder whether you can use Trulicity injections for weight loss, too.

Can you use Trulicity injections for weight loss?

The short answer is no. While Trulicity has yielded some weight loss in people with type 2 diabetes,¹ this is not the primary purpose of the drug. Trulicity was designed as a type 2 diabetes drug and is only licensed in the UK for blood sugar control.
That means it shouldn't generally be prescribed for weight loss – and any prescriptions of this nature would be considered 'off-label'. This is when a drug is prescribed for something it isn't licensed for.
Where losing weight is the goal, medical professionals and regulatory bodies recommend using licensed and clinically proven weight loss treatments. That includes Mounjaro and Wegovy. 

Why is Trulicity not approved for weight loss?

Regulatory bodies – such as the FDA in the US and the MHRA in the UK – conduct clinical trials to ensure a drug is safe for use.
However, these trials generally focus on one particular use for the drug. Wegovy and Mounjaro, for example, underwent extensive trials that focused explicitly on weight loss as the end goal.² ³

Trulicity's trials focused on testing the drug as a treatment for type 2 diabetes. During these trials, researchers also looked for changes in weight among participants – but this wasn't the main goal of the studies.⁴
This doesn't mean it isn't safe as a weight loss treatment. However, it does mean that its safety and effectiveness as solely a weight loss drug are not fully understood.

H3: Could Trulicity become a licensed weight loss treatment? 

Perhaps. However, it's worth considering that a comparison study has already shown that Wegovy outperforms Trulicity in terms of weight loss.⁵
In the SUSTAIN 7 trial, those receiving the highest tested dose of semaglutide lost 6.5 kg on average. However, those receiving the highest tested dose of dulaglutide – the active ingredient in Trulicity – lost an average of 3kg. 
Trulicity is an effective treatment for type 2 diabetes. However, you could argue that there's little point in licensing it for weight loss when more successful treatments like Wegovy are already available.

H3: Access expert-supported, clinically proven weight loss treatments with SemaPen

SemaPen is a weight loss clinic specialising in expert-led treatments for obesity . That includes the clinically proven weight loss injections Wegovy and Mounjaro, as well as SemaHealth – our dietitian-led meal replacement and fitness programme.
When you join our programmes, you can expect:

  • Around 21% weight loss with Mounjaro³
  • Around 15% weight loss with Wegovy²
  • Between 12% and 15% weight loss with SemaHealth⁶

But it's our expert support that really sets us apart. All our programmes are designed by UK obesity specialists and include tailored support to help you achieve your goals and learn healthy lifelong habits.

Ready to take the next step on your weight loss journey? You can find out if you're eligible today by taking our simple digital consultation .

Sources

1. Bonora, E. et al. (2021) "Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11" Diabetes Obesity Metabolism , 23(10) https://doi.org/10.1111/dom.14465
2. Wilding, J.P.H. et al. (2021) "Once-weekly semaglutide in adults with overweight or obesity" The New England Journal of Medicine, 384(11) https://doi.org/10.1056/NEJMoa2032183

3. Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" The New England Journal of Medicine, 387(3) https://doi.org/10.1056/NEJMoa2206038
4. Frias, J.P. et al. (2021) "Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)" Diabetes Care , 44(3) https://doi.org/10.2337/dc20-1473

5. Pratley, R.E. et al. (2018) "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial" The Lancet Diabetes & Endocrinology , 6(4) https://doi.org/10.1016/s2213-8587(18)30024-x

6. Valabhji, J. et al. (2024) "Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation" The Lancet Diabetes & Endocrinology , 12(9) https://doi.org/10.1016/S2213-8587(24)00194-3

This article was reviewed and approved by Lujain Alhassan, Bariatric Dietitian, and Sarah Abdula, Specialist Dietitian, on 3 December 2025.

  • Average 15-21% weight loss*
  • Tailored programmes built by real experts
  • Targeted support to make success feel simpler
  • Unique app with weight loss tools and lessons

Your journey starts here

Start your personalised weight loss plan in minutes.

1

Start your online consultation

2

Get approved by our clinical team

3

Begin your programme

Get started
Get the key facts about carbohydrates. Learn about their role in weight management
by Simon Edward 10 April 2026
Get the key facts about carbohydrates. Learn about their role in weight management and where they fit into a balanced diet.
Just starting out on your journey to sustainable health? Explore simple, evidence-based weight loss
by Simon Edward 6 April 2026
Just starting out on your journey to sustainable health? Explore simple, evidence-based weight loss tips for beginners.
Taking Mounjaro weight loss injections might affect how warfarin tablets are absorbed into the body.
by Simon Edward 31 March 2026
Taking Mounjaro weight loss injections might affect how warfarin tablets are absorbed into the body. Learn what this means for you as a patient.
Compounded semaglutide is an unlicensed version of the active ingredient found in Wegovy.
by Simon Edward 31 March 2026
Compounded semaglutide is an unlicensed version of the active ingredient found in Wegovy. Get all the straight facts in our quick guide.
A new tablet-based medication has beaten oral semaglutide (Rybelsus) for weight loss.
by Simon Edward 30 March 2026
A new tablet-based medication has beaten oral semaglutide (Rybelsus) for weight loss. Let's unpack the results to see what they really mean.
Is there a secret to maximising weight loss on Mounjaro? Follow our step-by-step guide
by Simon Edward 27 March 2026
Is there a secret to maximising weight loss on Mounjaro? Follow our step-by-step guide for straight facts and evidence-based tips.
Are you planning to take your Wegovy or Mounjaro weight loss pens abroad? Here are all the key facts
by Simon Edward 23 March 2026
Are you planning to take your Wegovy or Mounjaro weight loss pens abroad? Here are all the key facts you need to know.
There are many causes of obesity, but can genetics play a part? Learn how
by Simon Edward 20 March 2026
There are many causes of obesity, but can genetics play a part? Learn how our DNA can influence our weight, and what we can do about it.
Learn about the link between obesity and kidney stones, and whether weight loss medication can help
by Simon Edward 16 March 2026
Learn about the link between obesity and kidney stones, and whether weight loss medication can help to reduce risk.
Want to improve your diet? Learn what protein is, how much you need
by Simon Edward 13 March 2026
Want to improve your diet? Learn what protein is, how much you need and how good nutrition supports healthy weight loss.
More posts